Effectiveness and Safety of Pharmacological Treatments for Chronic Inducible Urticaria: A Narrative Synthesis. (PubMed, J Clin Med) - Oct 17, 2026 - "Omalizumab was highly effective as second-line treatment for antihistamine-refractory patients, although relapse after discontinuation was common. In delayed-pressure urticaria dapsone and high-dose intravenous immunoglobulin yielded good responses...Emerging mast cell-depleting therapies (barzolvolimab, lirentelimab) showed promising effectiveness, while the interleukin-1 inhibitor rilonacept failed to demonstrate clinical benefit...Relapse after treatment cessation is frequent, highlighting the need for personalized long-term strategies. Novel endotype-specific treatments require dedicated CIndU trials, as current evidence is largely extrapolated from chronic spontaneous urticaria."
Journal • Review • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria
|
|
Aikaterini Tsiogka; Alexandros I Stratigos; Dimitrios Rigopoulos; Eleni Chatzidimitriou; Elisavet Tsiogka; Ioannis-Alexios Koumprentziotis; Michael Makris; Stamatios Gregoriou
|